Abstract
Improving the treatment of neurodegenerative disorders such as Parkinson’s (PD) and Alzheimer’s disease (AD) has always been challenging. Compared with oral drug administration, nasal mucosa has emerged as a convenient target tissue for drug delivery because of its accessibility, high blood perfusion, greater surface area, permeability and ability to escape the first-pass metabolism. The BBB is the least reachable portion of the human body to active pharmacological molecules. While useful in the treatment of neurodegenerative disorders, conventional approaches fail to achieve maximum effectiveness. Hence, there is a need to invent therapeutic alternatives. This review comprises a brief explanation of the currently developed nose-to-brain drug delivery systems in treating neurodegenerative disorders. It further contrasts the strengths, disadvantages, and future viewpoints from which innovative drug research and therapy can be based.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
